Nicotinic agonists - Open Access .click

Results 111 to 120 of about 30,934 (191)

GLP‐1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions

Clinical and Translational Science, Volume 18, Issue 6, June 2025.
ABSTRACT Glucagon‐like peptide‐1 agonists (GLP‐1A) are increasingly prescribed to treat obesity and type 2 diabetes mellitus in children and adolescents. Emerging evidence suggesting neuropsychiatric effects presents an opportunity for pediatric psychopharmacology but requires careful consideration of potential adverse effects and risk of misuse.
Michael Bartkoski +2 more
wiley +1 more source

Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes

Journal of Internal Medicine, Volume 297, Issue 6, Page 584-607, June 2025.
Abstract Cardiometabolic diseases—including Type 2 diabetes and obesity—remain leading causes of global mortality. Recent advancements in metabolomics have facilitated the identification of metabolites that are integral to the development of insulin resistance, a characteristic feature of cardiometabolic disease. Key metabolites, such as branched‐chain
David Rizo‐Roca, John D. Henderson, Juleen R. Zierath +2 more
wiley +1 more source

Recent Advances in the α‐Hydrazination (α‐Amination) of Carbonyl Compounds

European Journal of Organic Chemistry, Volume 28, Issue 17, May 21, 2025.
In recent years, notable progress has been achieved in the α‐hydrazination (α‐amination) of carbonyl compounds, especially in the direct asymmetric electrophilic α‐hydrazination with dialkyl azodicarboxylates. This review summarizes all the methods that appeared over the past decade, categorized based on the type of the reactive chiral intermediate ...
Dina Scarpi, Samuele Visi, Ernesto G. Occhiato +2 more
wiley +1 more source

Effectiveness of nicotinic agonists as desensitizers at presynaptic α4β2- and α4α5β2-nicotinic acetylcholine receptors. [PDF]